Roche extends deadline for Spark Therapeutics shareholders in $4.8B deal

Swiss pharmaceutical giant Roche has extended its tender offer for the outstanding shares of Philadelphia gene therapy company Spark Therapeutics to May 2. The $114.50 per share tender offer was set to expire at the end of the day on April 3. About 11.3 million shares of Spark (NASDAQ: ONCE), which represents about 29 percent of Sparks’s outstanding shares, had been validly tendered and received prior to the extension. Roche, which needs at least 50 percent of shares to be tendered to move forward…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news